




Uptake of PrEP services among MSM in Malaysia: preliminary findings from myPrEP demonstration project

Howie Lim, Mohd Akbar, Raymond Tai, Andrew Yap, Meng Li Chong, Nishaan, Jeffrey Wickersham, Iskandar Shah


Australian HIV & AIDS Conference, 26 September 2018

Background: HIV transmission by Risk Factor in 2016




Source: HIV/STI Sector, Division of Disease Control, Ministry of Health Malaysia

Figure Proportion of newly reported cases of HIV infection by route of transmission, Malaysia, 2008 - 2016



Source: Malaysian AIDS Council, 2017

Number of newly reported cases of HIV infection MSM, Malaysia, 2008-2016



Source: Malaysian AIDS Council, 2017

HIV Incidence in re-testers

CHCC Clinic, PT Foundation

	Newly tested	HIV infected	HIV prevalence	PY of follow-up re-testers	Newly HIV-infected	HIV incidence density
Year	N	n	% (95% CI)	N	n	(n/N) (95% CI)
2014	1126	107	9.5 (7.9-11.4)	37.18	4	10.1 (4.0-28.7)
2015	1253	124	9.9 (8.4-11.7)	136.77	8	5.8 (2.9-11.7)
2016	824	84	10.2 (8.3-12.5)	202.98	9	4.4 (2.3-8.5)
2017	776	102	13.1 (10.9-15.7)	277.57	12	4.3 (2.5-7.6)
Total	3979	417	10.5 (9.6-11.5)	654.49	33	5.0 (3.6-7.1)

PY, person years; CI, confidence interval

[HIV prevalence and incidence among men who have sex with men attending a community health center, Kuala Lumpur 2014-2017]

F.Van Griensven et al. Abstract submitted to AIDS 2018

PrEP Timelines in Malaysia



Timeline	PrEP Initiative	Lead partner organization(s)
Aug 2015	Inclusion of PrEP in National Strategic Plan (NSP) to End AIDS (2016-2030)	MOH
Sept 2015	Regional PrEP Consultation (PrEPARING Asia), Bangkok	Led by APCOM
March 2016	Online PrEP Survey in MSM	International HIV Alliance
May 2016	National PrEP Consultation	MOH, WHO, UNAIDS, International HIV Alliance, APCOM (Global Fund)
May 2016	Formation of PrEP Working Group	
Sept 2016	Completion of National PrEP and nPEP guidelines	MASHM Out of pocket PrEP


PrEP Timelines - Cont

Timeline	PrEP Initiative	Lead partner organization(s)
Oct 2016	1 st meeting of PrEP working group	
Jan 2017	MASHM GP course	MASHM, MAC
Jan 2017	1 st Asia Pacific PrEP Implementation Meeting, Bangkok	USAID, PEPFAR, FHI 360, TRC ARC
Dec 2017	Price reduction of generic TDF/FTC (generic competition)	Medispec, Cipla
Jan 2018	2 nd Asia Pacific PrEP implementation meeting, Bangkok	
March 2018	Pilot multi-site PrEP demonstration project in MSM	UNAIDS/WHO/GF
July 2018	Pilot PrEP demonstration project in TGW	NIH/ Yale University

LEVELS OF PREP AWARENESS AND ACCEPTABILITY

Have you heard of PrEP?





My PrEP Project

- Pilot demonstration project
- Funded by UNAIDS/WHO/Global Fund
- Partnered with Malaysian AIDS Council
- 150 HIV negative MSM at high risk of HIV infection over 12 months
- Free Generic Truvada based PrEP donated by Medispec
- 3 study sites:
 - 1) University of Malaya Medical Center (UMMC)
 - 2) The Red Clinic, a private health clinic
 - 3) Community Health Care Center (CHCC) of Pink Triangle Foundation, the largest HIV CBO in Malaysia



Overall Objective

- To determine the **acceptability and feasibility of the use of PrEP** during a **12 month study period in in Kuala Lumpur in HIV negative MSM at high risk of HIV infection**
- Study population: MSM
- Planned sample size: 150
- 2 phase:
 - Site assessment & protocol refinement
 - Feb 2017: Dr. Frits van Griensven (Thailand), Mr. Danvic Rosadino(PrEP, Love Yourself)
 - Demonstration project, commenced March 2018

Secondary Objectives

- 1) Assess adherence (including adherence and exposure patterns and risk coverage), retention (loss to follow-up and drop-out) and client satisfaction (including reported secondary benefits of PrEP)
- 2) Record physical and biological side-effects and events associated with PrEP intake
- 3) Determine HIV and STI prevalence and incidence
- 4) Establish successful linkage to HIV care and evaluate STI treatment and vaccination
- 5) To identify and inform the most acceptable PrEP service delivery model and the role of a CBO in the provision of PrEP

Study Drug & Drug availability Generic TDF/FTC for use as PrEP

- Generic co-formulated dual oral emtricitabine / tenofovir (FTC/TDF) – Tenof-Em (Hetero, India)
- Drugs are provided free to participants (donated by Medspec)
- Generic TDF/FTC
 - No license required for use as PrEP
 - Medispec will apply for extension of application for PrEP, if at all necessary

Inclusion Criteria


- Age ≥ 18 years
- Able to provide written informed consent
- HIV negative on 4th Gen HIV Ag/Ab test performed at screening
- Creatinine clearance of > 60 mL/min
- Evidence of substantial risk of HIV infection during the past 6 months:
 - Condomless anal intercourse with at least 1 male sex partner
 - Anogenital STI
 - Exchanged money or goods for sex
 - Used recreational drugs in the sexual context
 - Used PEP

Exclusion Criteria


- Current HIV infection
- Signs or symptoms of acute HIV infection
- Creatinine clearance < 60 mL/min (at one occasion)
- Current use of nephrotoxic drugs
- Unable to attend follow-up appointments for the duration of the project

NB: Hep B sAg positive patients – not excluded



Current status of Enrollment (17 March-24 Sept 2018)




Main Reasons for Ineligibility



Baseline Data
Demographics
(n=130)




Age Group



- 18 - 25
- 26 - 35
- 36 - 45
- 46 - 55

- Youngest = 21yo
- Oldest = 50yo
- Mean = 31yo


Education Level



- Up to high school
- Up to University degree
- Postgraduate


Sexual Behaviour Eligibility

Past 6 months




- History of unprotected anal intercourse with at least 1 male sex partner of HIV+ or unknown
- History of anogenitally STI
- Exchanging money or goods for sex
- Using drugs for sexual pleasure
- Used PEP for HIV

Sexual Behaviour Eligibility Factors Score (count)




Regular Male Partners


- Mean regular male partner in the past 3 months = 3.59




Frequencies of Condom use in the Past 3 Months




Group sex in the past 3 Months




Exchanging money or goods for sex in the past 3 months



ChemSex in Past 3 Months



Compliance Rate



Based on Weekly Online Diary, Minimum of 4 episodes of pill taking per week

Few lessons Learned

- There is an urgent need to prioritize PrEP as an HIV prevention tool for high risk MSM in Malaysia
- PrEP service is very new in Malaysia
- Promote PrEP awareness and create demands
- Clients are willing to pay for PrEP if delivered at an affordable price
 - No country in Asia (yet!) provides free PrEP outside implementation projects
- Be innovative- think of novel and accessible service delivery models
 - Primary Care Clinics with MSM case load are currently the best sites to deliver PrEP
 - MSM-led clinics are the most accessible service delivery model but will require regulatory and policy changes to make it sustainable

Venue: Red Clinic, S23-P1, Block B, Jaya One Mall, P.J.

5TH MAY 2018 | SATURDAY | 3 - 5PM

HIV.PrEP Seminar 2018

FEATURED SPEAKERS



Dr. ROSVINDER SINGH
 > 10 years experiences in
 - HIV Knowledge sharing



Dr. ANDREW YAP
 participated in PrEP
 conferences and research



EZRA AKBAR
 on going for PrEP research

ORGANIZED BY




Topics

1. PrEP
 - What is PrEP?
 - Why take PrEP?
 - Should one consider PrEP?
 - How effective is PrEP?
 - Does PrEP have side effects?
 - How one can start on PrEP?
 - How long does one need to take PrEP?
 - Should one stop using condom when taking PrEP?
 - Is PrEP effective for vaginal & anal sex?
2. PEP
 - What is PEP?
 - When one should take PEP?
 - Does PEP have side effects?
 - How long does one need to take PEP?
3. HIV & AIDS
4. STDs
 - Chlamydia
 - Gonorrhoea
 - Syphilis
 - Herpes

RSVP BEFORE 23.04.18 (Monday)

*Subject to operations plan on that day

Click on the photo to start tagging. **Finished tagging**



Acknowledgements

